Drug news
NICE recommends Cosentyx (secukinumab) to treat Ankylosing Spondylitis.- Novartis
The National Institute for Care and Health Excellence (NICE) has published a positive Final Appraisal Determination recommending Cosentyx (secukinumab) from Novartis as an option for adult patients with Ankylosing Spondylitis who have failed to respond adequately to conventional therapy.The list price of secukinumab is �9,140.85 per person in the first year and �7,312.68 in subsequent years, and the drug is recommended for NHS use if Novartis provides an agreed discount in a patient access scheme.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.